Medivir

Medivir Tangible Book Value per Share

The Tangible Book Value per Share of Medivir (MVIR.ST) as of Oct 16, 2026 is 0.59 SEK. In the previous year, Tangible Book Value per Share was 0.04 SEK — a change of 1,277.32% (higher).

Tangible Book Value per Share

0.59SEK

YoY

1,277.32%

Last updated:

Tangible Book Value per Share of Medivir is 2025 0.59 SEK. Tangible Book Value per Share of Medivir was 2024 0.04 SEK. It decreases by 1,277.32% higher compared to the previous year.

The Medivir Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
0.69 SEK
Jan 1, 2019
0.41 SEK
Jan 1, 2020
0.10 SEK
Jan 1, 2021
0.41 SEK
Jan 1, 2022
0.22 SEK
Jan 1, 2023
0.27 SEK
Jan 1, 2024
0.04 SEK
Jan 1, 2025
0.59 SEK
The Medivir Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
0.59SEK+1,277.32%
0.04SEK-84.21%
0.27SEK+26.05%
0.22SEK-47.80%
0.41SEK+305.47%
0.10SEK-75.29%
0.41SEK-40.03%
0.69SEK-40.16%
1.15SEK-70.34%
3.86SEK+33.33%
2.90SEK-29.06%
4.08SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medivir Stock analysis

What does Medivir do? Medivir AB is a biotechnology company based in Huddinge, Sweden, operating within the health care sector. The company has a small team of nine full-time employees. Founded in 1996, Medivir AB went public on February 29, 1996, and is listed on the Stockholm Stock Exchange under the ticker MVIR.ST. The company's website is www.medivir.se. Medivir focuses on the development of pharmaceutical products, particularly in the areas of protease inhibitor design and nucleoside and nucleotide science. Their clinical pipeline includes remetinostat, a topical histone deacetylase inhibitor in phase II trials for cutaneous T-cell lymphoma, and birinapant combined with Keytruda for solid tumors in phase I trials. Additionally, MIV-818, a nucleotide-based prodrug, is in phase I trials for liver cancer, and MIV-711, a cathepsin K inhibitor, is in an IIa extension study for osteoarthritis. The company collaborates with other institutions on research projects. Medivir AB is dedicated to addressing unmet medical needs through innovative therapeutic approaches. Medivir is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medivir stock

Tangible Book Value per Share of Medivir is 0.59 SEK in 2025.

Tangible Book Value per Share of Medivir changed from 0.04 SEK to 0.59 SEK, representing a 1,277.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Medivir since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Medivir

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Medivir